Diaryl urea derivatives have exhibited a broad spectrum of biochemical effects and pharmaceutical applications. Several diaryl urea derivatives such as sorafenib, regorafenib, linifanib, and tivozanib and lenvatinib are in clinical trial or clinical use. Therefore, development of small molecules within the diaryl urea scaffold with the ability of binding to variety of enzymes and receptors in the biological system are an interesting topic for researchers. Sorafenib as a diaryl urea derivative is a well-known anticancer agent. Corresponding to available information about biological activities of quinoxaline moieties, based on sorafenib scaffold, several structures were designed by replacement of pyridyl carboxamide group of sorafenib with quinoxalindione moiety. A total of 14 novel compounds in 7 synthetic steps were synthesized. Briefly, the amino group of p-aminophenol was first protected followed by O-arylation of 4-acetamidophenol with 5-chloro-2-nitroaniline to provide 5-(4-acetamidophenoxy)-2-nitroaniline. Reduction of the nitro group of 5-(4-acetamidophenoxy)-2-nitroaniline and cyclization of diamine N-(4-(3,4-diaminophenoxy) phenyl) acetamides with oxalic acid afforded compound N-(4-((2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)oxy)phenyl) acetamides which on deacetylation gave compounds 6-(4-aminophenoxy) quinoxaline-2,3 (1H, 4H)-diones. Then resultant compounds, 6-(4-aminophenoxy) quinoxaline-2,3 (1H, 4H)-diones were reacted by appropriate isocyanates/ carbamates to give the target compounds 1-(4-((2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)oxy)phenyl)-3-phenylureas. The structures of compounds confirmed by proton nuclear magnetic resonance ( 1 H NMR), mass spectrum and Fourier transform infrared (FT-IR).
INTRODUCTION
Diaryl urea derivatives have broad spectrum of biochemical effects and pharmaceutical applications. In recent years, there have been intense research focused on the design and development of diaryl urea derivatives as a class of antitumor agents (1-3). There are several diaryl urea derivatives that are on clinical trial or have been used clinically such as sorafenib, regorafenib, linifanib, tivozanib and lenvatinib ( , an oral, multireceptor tyrosine kinase inhibitor, was approved by FDA to treat patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (6) . Tivozanib (AV-951 ® ) an orally bioavailable quinoline-urea derivative inhibitor of vascular endothelial growth factor receptors has demonstrated safety and efficacy for patients with advanced or metastatic renal cell carcinoma (7) . Linifanib (ABT-869 ® ) shows significant clinical activity as monotherapy in patients with advanced hepatocellular carcinoma (8) . Nowadays development of small molecules within the diaryl urea scaffold, with the binding ability to a variety of enzymes and receptors in the biological systems is a topic of interest for researchers (9) (10) (11) (12) (13) .
In this study, we focused on modification of pyridyl ring of sorafenib by replacing of this group with quinoxalindione moiety (Fig. 2) according to the structure activity relationship studies (SAR). Nitrogen atoms in the pyridyl carboxylamide moiety of sorafenib are essential for binding to ATP-binding pocket of kinase. Quinoxalindione is an aromatic heterocycle containing two nitrogen atoms in its structure which is comparable with pyridyl carboxamide moiety in terms of size and polarity. Presence of amide in this structure could impart susceptibility to act at target sites of sorafenib. Based on previous SAR of sorafenib analogs, rigidity is beneficial for improvement of antitumor activity of these derivatives; for instance, pyridoimidazolone and pyridopyrazinone analogs of sorafenib showed enhanced inhibitory potency toward B-Raf inhibition and cellular assay (14, 15) . Our previous quantitative SAR (QSAR) model studies on a series of diaryl urea derivatives revealed that rigidity and aromaticity are two important factors to improve activity for these derivatives. Therefore, quinoxalindione as a bicyclic heterocycle with six membered rigid ring, can afford rigidity in sorafenib framework (16) (17) (18) (19) (20) (21) (22) . Quinoxaline and its derivatives showed a wide range of applications in medicine due to their biological activities, which include antimicrobial, antiproliferative, and anticancer activities (23, 24) . Thus significant biological activities of quinoxalindione derivatives makes it a good fragment in drug design (16) (17) (18) (19) (20) (21) (22) . In this work, a total of 14 novel diarylurea derivatives were designed and their successful synthesis were confirmed by proton nuclear magnetic resonance ( 1 H NMR), mass spectroscopy and Fourier transform infrared (FT-IR).
MATERIALS AND METHODS
All chemicals used for the synthesis of the compounds were purchased from Merck or Sigma (Germany). The purity of the compounds was investigated by thin layer chromatography (TLC) on silica gel plate using appropriate solvents. All reactions were monitored by TLC as described. Melting points were determined with an electro thermal 9200 capillary melting point apparatus (Germany). The IR spectra were recorded with a WQF-510 ratio recording FTIR spectrometer (China) using a KBr disc (γ, cm -1 ). The 1 H NMR spectra were recorded using a Brucker 400 MHz spectrometer (Germany) and (D6) dimethyl sulfoxide (DMSO) or deuterated chloroform (CDCl 3 ) were used as solvents, and chemical shifts (δ) were expressed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Splitting patterns are as follows: s, singlet; d, doublet; m, multiplet; b, broad; dd (doublet of doublet . ) Mass spectra were acquired with a Platform II Mass Spectrometer from Micro mass (Shimadzu, Japan). Electron impact ionization was performed at an ionizing energy of 70 ev.
RESULTS

Details of preparation procedures and chemistry of synthesized compounds
Synthetic route for the preparation of target compounds 15a-15g and 16a-16g are illustrated in Scheme 1 where the different starting materials 1 and 2 were utilized respectively and the details of synthesis provided in the following sections.
Synthesis of N-(4-hydroxyphenyl) acetamide (3) and N-(4-hydroxy-2-methylphenyl) acetamide (4)
A mixture of p-aminophenol (146 mmol, 16 g), H 2 O (43 mL) and acetic anhydride (18 mL) was heated at 100 °C until solid was dissolved, the mixture was heated for an additional 20 min to complete the reaction, the mixture was then cooled in ice bath. Crystals were collected by filtration and purified by recrystallization in ethanol to afford compound 3 (13 g 
Synthesis of N-(4-(1,2,3,4-tetrahydro-2,3-dioxoquinoxalin-6-yloxy) phenyl) acetamide (9) and N-(4-(1,2,3,4-tetrahydro-2,3-dioxoquinoxalin-6-yloxy)-2-methylphenyl) acetamide (10)
A solution of oxalic acid dihydrate (14 mmol, 1764 mg) in HCl (25 mL, 0.5 M) was heated to 100 °C, followed by addition of diamine 7 (14 mmol, 3598 mg) with stirring at 100 °C for 3-4 h. Completion of the reaction was confirmed by TLC .The mixture was cooled by addition of ice. To a solution of aniline 13c-13g (1 mmol) in anhydrous tetrahydrofuran (THF) (9 mL) at 0 o C, pyridine (1.3 mmol, 108 µL) was added, followed by phenyl chloroformate (1.2 mmol, 154 µL). The mixture was kept at 0 °C for 15 min, then allowed to warm at room temperature and stirred for 24 h. The solvent was evaporated and the residue poured in EtOA (15 mL).
The suspension was washed with HCl (15 mL, 1 M), water (15 mL), saturated aqueous NaHCO 3 (15 mL) and brine (15 mL). The organic layer was dried over MgSO 4 and evaporated. The solid obtained was washed with diethyl ether to afford the products 14c-14g as fallow:
Phenyl 2-fluoro-5-(trifluoromethyl) phenylcarbamate (14c)
Compound 14c was obtained from 2-fluoro-5-(trifluoromethyl) aniline (8 mmol,1 mL) as a white solid (830 mg, 34%), M.p. 90-91°C. 
Phenyl 2-chlorophenylcarbamate (14d)
Compound 14d was obtained from 2-chloroaniline (11.1 mmol, 1 mL) as a white solid (420 mg, 15%), M.p. 53-55 °C. 
Phenyl 5-(trifluoromethyl)-2-methoxyphenylcarbamate (14g)
Compound 14g 
Phenyl 4-chloro-3-(trifluoromethyl) phenylcarbamate (14f)
Compound 14f 
Synthesis and characterization of diaryl urea derivatives (15a-15g) and (16a-16g)
Diary lurea compounds 15a-15b and 16a-16b was synthesized from amine 11-12 and appropriate aromatic isocyanate, phenyl isocyanate (14a) or 3-(trifluoromethyl) phenyl isocyanate (14b) and diaryl urea compounds 15c-15g and 16c-16g from amine 11-12 and appropriate aromatic carbamate 14c-14g that previously was described synthesis procedure's.
General procedure for synthesis of diaryl urea compounds (15a-15b) and (16a-16b)
For synthesis of compounds (15a-15b), solution of compound 11 (1 eq) in DMSO (2 mL) and corresponding aromatic isocyanate, 3-(trifluoromethyl) phenyl isocyanate or phenyl isocyanate 14a-14b (1eq) was stirred overnight at room temperature. The reaction mixture quenched by addition of water and the perticipitae was collected and washed with large amount of dichloromethane (DCM) and (EtOAc) to obtain the desired diarylurea compounds 15a-15b as brown color powder.
Compounds (16a-16b) were synthesized from amine 12 according to procedure described for synthesis of compounds (15a-15b).
General procedure for synthesis of diarylurea compounds (15c-15g) and (16c-16g)
For synthesis of compounds (15c-15g), solution of compound 11 (1 eq) in DMSO (2 mL) and appropriate aromatic carbamate 14c-14g (1 eq) was heated at 85 °C and stirred overnight. After cooling to room temperature the reaction mixture was quenched by addition of water and the precipitate was collected and washed with large amount of DCM and EtOAC to obtain the desired diary lurea compounds 15c-15g as brown color solids.
Compounds (16c-16g) was synthesized from amine 12 according to the procedure described for synthesis of compounds (15c-15g).
1-(4-(1, 2, 3, 4-tetrahydro-2, 3-dioxoquinoxalin-7-yloxy) phenyl)-3-phenylurea (15a)
Brown 61(m, 4H, H 1,3,25,23 ), 8.78 (s, 1H, H 2 ( 4 -(1, 2, 3, 4-tetrahydro-2,3- 
1-
Brown powder, yield: 15%, M.p. >300 °C. 1 (1- (4-(1, 2, 3 
, 4-tetrahydro-2, 3-dioxoquinoxalin-7-yloxy) phenyl)-3-(3-(trifluoromethyl) phenyl) urea (15b)
Brown powder, yield: 65%, M.p. >300 °C. 
1-(4-(1, 2, 3, 4-tetrahydro-2, 3-dioxoquinoxalin-7-yloxy)-2-methylphenyl)-3-(3-(trifluoromethyl) phenyl) urea (16b)
Brown 
1-(4-(1, 2, 3, 4-tetrahydro-2, 3-dioxoquinoxalin-7-yloxy) phenyl)-3-(5-(trifluoromethyl)-2-methoxyphenyl) urea (15g)
DISCUSSION
NMR characterization
In step 1 protection of amino group of paminophenol was confirmed by a singlet peak at 1.97 ppm due to the protons of acetamide methyl group. Moreover, NH of acetamide and phenolic OH groups demonstrated two separate singlet peaks around 9 ppm. In step 2, disappearance of phenolic OH peak at 9 ppm and appearance of 3 aromatic hydrogens peak at 7-8 ppm confirmed O-arylation reaction. In step 3, reduction of nitro group was confirmed by shift of aromatic hydrogen at ortho position of nitro group from 8 ppm to 6 ppm in reduced compound. In step 4, cyclization of diamine and formation of key quinoxalindione moiety intermediate was confirmed by shift of three aromatic protons of this group from high field around 6 ppm to lower field around 7 ppm due to electron withdrawing effect of carbonyl group of quinoxalindione. Furthermore, 2 singlet peaks around 12 ppm represent 2 NH groups of quinoxalindione substructure. In step 5, due to deacetylation methyl peak at 2 ppm is diminished and a broad peak around 5 ppm represent NH 2 group. In final step conjugation of isocyanate or N-phenylcarbamate compound with intermediate is confirmed by two significant singlet bonds around 8-9.5 ppm and appearance of several aromatic hydrogens at 7-8 ppm.
FT-IR characterization
The structures of synthesized compounds were confirmed by means of FT-IR spectroscopy. The main IR vibrational bands of the synthesized compounds were found in their expected regions. Protection of amine group of p-aminophenol was confirmed by appearance of acetamide carbonyl group band at 1655 cm -1 . O-arylation was confirmed by two significant bands at 1572 and 1333 cm -1 which were attributed to nitro group. In step 3, disappearance of nitro group peaks at 1572 and 1333 cm -1 and appearance of several peaks at 3200-3369 cm -1 region confirmed nitro reduction to amine. In step 4, cyclization of diamine and formation of quinoxalindione was confirmed by appearance of new bond at 1685 cm -1 assigned to carbonyl groups of quinoxalindione moiety. In step 5, after deacetylation, carbonyl groups of quinoxalindione moiety bands were shifted to1720 cm -1 from 1685 cm -1 and the carbonyl of acetamide group band disappeared from 1655 cm -1 . In step 6, formation of diaryl urea derivatives was confirmed by strong broad band at 1680-1695 cm -1 assigned to carbonyl stretching of quinoxalindione moiety and carbonyl of urea group.
CONCLUSION
In the current work we report the synthesis of sorafenib derivatives 15a-15g and 16a-16g which differ from sorafenib by replacing pyridyl carboxamide ring of sorafenib with quinoxalindione moiety. A 7-step synthetic pathway includes preparation of N-(4-hydroxyphenyl) acetamides 3-4, N-(4-(3 -amino -4 -nitrophenoxy) phenyl) acetamides 5-6, N-(4-(3,4-diaminophenoxy) phenyl) acetamides 7-8, N-(4-((2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)oxy)phenyl) acetamides 9-10, 6-(4-aminophenoxy) quinoxaline-2,3 (1H, 4H)-diones 11-12, phenyl phenylcarbamates 14c-14g and the target compounds 1- (4-((2,3-dioxo-1,2,3 , 4-tetrahydroquinoxalin-6-yl)oxy)phenyl) -3-phenylureas 15a-15g and 16a-16g. The final compounds as well as intermediates were chemically characterized. These compounds will be subjected to biological evaluations to investigate their possible cytotoxic and antimicrobial activities.
